Buprenorphine
Depressive Disorder
Marta Peciña, MD PhDSmall moleculePhase 4 / ApprovedDormant
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 69/ 100
- Competitive Position
- 73/ 100
Competitive context
78 Active assets in the Depressive Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Brexpiprazole Dr. Albert Kar-Kin Chung | Phase 4 | A |
Jnj-54135419 Chinese PLA General Hospital | Phase 4 | BBB |
Saredutant Sanofi | Phase 3 | BBB |
Escitalopram Poznan University of Medical Sciences | Phase 4 | BBB |
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE VA Office of Research and Development | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Buprenorphine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →